New drug combo trial offers hope for Tough-to-Treat sarcoma
NCT ID NCT05099666
Summary
This study is testing whether adding a new drug called lurbinectedin to a standard chemotherapy (doxorubicin) works better than the standard drug alone for people with advanced leiomyosarcoma, a type of soft-tissue cancer. The first part of the study aims to find the safest dose of the combination. The second part will randomly assign participants to receive either the combination or the standard drug to see which is more effective at controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LEIOMYOSARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02115, United States
-
Mayo Arizona
Phoenix, Arizona, 85054, United States
-
Mayo Jacksonville
Jacksonville, Florida, 32224, United States
-
Mayo Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.